US20050260200A1 - Antigenic peptides reacting with anti-ovary antibodies - Google Patents
Antigenic peptides reacting with anti-ovary antibodies Download PDFInfo
- Publication number
- US20050260200A1 US20050260200A1 US11/142,327 US14232705A US2005260200A1 US 20050260200 A1 US20050260200 A1 US 20050260200A1 US 14232705 A US14232705 A US 14232705A US 2005260200 A1 US2005260200 A1 US 2005260200A1
- Authority
- US
- United States
- Prior art keywords
- seq
- process according
- sequence
- amino acid
- oligopeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 53
- 230000000890 antigenic effect Effects 0.000 title abstract description 19
- 102000004196 processed proteins & peptides Human genes 0.000 title description 16
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 31
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 31
- 235000001014 amino acid Nutrition 0.000 claims description 45
- 150000001413 amino acids Chemical class 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 34
- 230000008569 process Effects 0.000 claims description 18
- 239000004215 Carbon black (E152) Substances 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- 229930195733 hydrocarbon Natural products 0.000 claims description 16
- 235000018417 cysteine Nutrition 0.000 claims description 14
- 230000002209 hydrophobic effect Effects 0.000 claims description 13
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 9
- 238000012986 modification Methods 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 7
- 230000003325 follicular Effects 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 230000005847 immunogenicity Effects 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 3
- 210000003756 cervix mucus Anatomy 0.000 claims description 2
- 150000001945 cysteines Chemical class 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 17
- 230000002163 immunogen Effects 0.000 abstract description 8
- OHOXVDFVRDGFND-YUMQZZPRSA-N His-Cys-Gly Chemical compound N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CS)C(=O)NCC(O)=O OHOXVDFVRDGFND-YUMQZZPRSA-N 0.000 abstract description 2
- RJBFAHKSFNNHAI-XKBZYTNZSA-N Thr-Gln-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N)O RJBFAHKSFNNHAI-XKBZYTNZSA-N 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000002611 ovarian Effects 0.000 description 15
- 230000000875 corresponding effect Effects 0.000 description 13
- 230000036512 infertility Effects 0.000 description 13
- 208000000509 infertility Diseases 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 230000002788 anti-peptide Effects 0.000 description 11
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000000287 oocyte Anatomy 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 206010036601 premature menopause Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 201000009273 Endometriosis Diseases 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000008175 FSH Receptors Human genes 0.000 description 2
- 108010060374 FSH Receptors Proteins 0.000 description 2
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000025237 Polyendocrinopathy Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 2
- 210000004246 corpus luteum Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- WBYOCCGHKAPLST-VZGOPMHCSA-N (3s)-3-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-6-amino-2-[[2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2,5-diamino-5-oxopentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-(4h-imidazol-4-yl)propanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]hexanoyl]amino]-3-sulfanylpro Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(N)=O)CC1C=NC=N1 WBYOCCGHKAPLST-VZGOPMHCSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000011707 Ovulation disease Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000055608 human beta subunit (81-95) follicle stimulating hormone Human genes 0.000 description 1
- 108700026359 human beta subunit (81-95) follicle stimulating hormone Proteins 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000017942 premature ovarian failure 1 Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
Definitions
- the present invention concerns immunology and its direct impact in endocrinology, both in man and in animals. More particularly, this impact concerns the reproductive system. It is in fact through pathologies such as repeated spontaneous abortions, antiphospholipid antibody syndrome and preeclampsia that dysimmune mechanisms have been observed in gynaecology and obstetrics.
- IVF in vitro fertilization
- the inventors of the present invention have surprisingly discovered that a well defined peptide sequence, which corresponds in its primary structure to a part of the ⁇ -subunit of FSH, displayed an antigenic and immunogenic character toward anti-ovary antibodies such as previously defined.
- ovarian auto-immunity is nowadays essentially addressed using animal tissue substrates or animal ovarian extracts (4).
- the ovarian extract used by MONCAYO et al. was of animal, namely bovine, origin. It has not been demonstrated that the antigens recognized were actually the same in the human species and in cattle.
- an antigenic peptide capable of replacing ovarian extracts, and follicle stimulating hormone (FSH or gonadotrophin A) which remains a product difficult to purify, and only on the market in recombinant forms, is provided.
- FSH or gonadotrophin A follicle stimulating hormone
- the first object of the invention is an oligopeptide consisting of the reference peptide sequence Thr Gln Cys His Cys Gly Lys Cys (SEQ ID NO: 5), or any peptide sequence, functional variant of the said reference sequence, in the sense that the first displays an antigenicity, and/or an immunogenicity toward anti-ovary antibodies equivalent to the antigenicity and/or the immunogenicity of the second.
- a functional variant of the said reference sequence is advantageously obtained by modifying the hydrocarbon residue of at least one of the amino acids of the said reference sequence, while conserving an antigenicity identical or similar to that of the said reference sequence, or else by modifying the hydrocarbon residue of at least one of the amino acids of the said reference sequence, while substantially retaining the hydrophilic/hydrophobic character of the said hydrocarbon residue.
- An oligopeptide of the invention can thus consist of a peptide sequence corresponding to the formula: Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8, in which formula:
- the said functional variant sequence corresponds to the formula Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8, in which formula:
- constituent radicals R1 and/or R2 and/or R3 and/or R4 and/or R5 and/or R6 and/or R7 and/or R8 of the said units are respectively selected among radicals conferring on the said units a hydrophilicity/hydrophobicity identical or similar to that of the respectively corresponding amino acids.
- the oligopeptide consisting of the peptide sequence SEQ ID No.1 for example may be cited.
- Example 2 below in fact demonstrates identical activity for the oligopeptides SEQ ID No.1 and 5.
- the oligopeptides SEQ ID No.2, 3 and 4 having weaker activity than the oligopeptides cited above, are considered in the present invention as functional variants.
- these oligopeptides are functional variants of SEQ ID No.5.
- oligopeptides described at the end of the specification are:
- the surprising feature of the invention is that the oligopeptides of the invention, such as those represented by SEQ ID No.1 and 5, the primary amino acid structure of which corresponds respectively to the amino acids 78-93 and 80-87 of the P-chain of FSH, although probably having a three-dimensional structure different from that of the ⁇ -chain of FSH, display an antigenic and/or immunogenic activity toward anti-ovary antibodies.
- the oligopeptide has the peptide sequence identified by SEQ ID No.5.
- the oligopeptide has the peptide sequence identified by SEQ ID No.1.
- the oligopeptide has the peptide sequence identified by SEQ ID No.2 or 3 or 4, as identified at the end of the specification.
- a second object of the present invention is an antigenic compound capable of being recognized by the anti-ovary antibodies, or an immunogenic compound capable of inducing the production of anti-ovary antibodies, the said compound corresponding to any one at least of the following definitions:
- Another object of the invention is a composition antigenic or immunogenic toward anti-ovary antibodies, including an antigenic or immunogenic compound such as defined above.
- a third object of the invention is a process for detection and/or quantification of anti-ovary antibodies in a biological sample, including the stage consisting in placing the said biological sample in contact with at least one peptide or one compound of the invention, and in observing the formation of an antigen-antibody complex between the said peptide or compound and an anti-ovary antibody.
- the formation of the aforesaid complex can be detected by different classical bioassay formats, known to the skilled person, such as immunocytochemical and immunoenzymatic (ELISA) techniques, competition techniques and “sandwich” techniques.
- ELISA immunocytochemical and immunoenzymatic
- the biological sample is advantageously selected among the blood serum, the follicular liquid, the peritoneal liquid, the cervical mucus and the saliva.
- the stage of observation of the formation of an antigen-antibody complex is preferably effected by the immunoenzymatic technique called ELISA, with which it has been possible to obtain results perfectly correlated those [sic] obtained by the reference technique for the skilled person, namely indirect immunofluorescence.
- the last objects of the invention are firstly a reagent for detection and/or quantification of anti-ovary antibodies including at least one peptide or one compound of the invention, and secondly a kit for detection and/or quantification of anti-ovary antibodies including at least the said reagent.
- a peptide sequence, functional variant of the reference peptide sequence is a sequence of amino acids, called modified, differing from the sequence (SEQ ID NO: 5) by modifications which confer on the said functional variant sequence an antigenicity identical or similar to that of the reference sequence.
- the modifications of the said sequence can concern its size, and each of the amino acids that constitute it.
- Such modifications are in particular selected among substitutions, deletions and additions of amino acids in the sequence of the first oligopeptide, but also among replacement of an amino acid of the L series by an amino acid of the D series, modification of the side-chains of the amino acids, modification of the peptide bonds such as carba, retro, inverso, retro-inverso, reduced or methylene-oxy bonds, subject to the condition that these modifications do not result in any significant alteration of the antigenic properties of the said sequence toward anti-ovary antibodies.
- an amino acid of SEQ ID No: 5 can be replaced by another amino acid of the same hydrophilicity/hydrophobicity or of comparable hydrophilicity/hydrophobicity.
- the competent skilled person who routinely utilizes the techniques at his disposal, in particular the techniques of automated peptide synthesis and the techniques of determination of the antigenicity of a peptide such as ELISA tests, is capable, in a first stage, of synthesizing a modified sequence such as defined above, and, in a second stage, of testing the antigenicity of the peptide obtained. If the latter displays an antigenicity at least substantially equivalent to that of the said reference sequence, it corresponds to the definition of functional variant sequence of the said reference sequence.
- the skilled person can in particular refer to the examples 2 and 3 below, which describe a protocol to be followed for comparing the antigenicity of two peptides toward AOAs.
- a compound of the invention includes a sequence of a variable number of amino acids, including at least the sequence of one oligopeptide of the invention. It can in particular consist of a protein, a glycoprotein, a fusion protein or a fusion peptide. It can moreover be bound on a solid support.
- An oligopeptide or a polypeptide of the invention may be obtained by any obtention route and in particular chemical synthesis or genetic recombination.
- the objects of the invention are also of value outside the study of physiopathogenic hypotheses relating to certain clinical situations, such as mentioned previously.
- the provision of a reliable test for estimation of anti-ovary antibodies can have other diagnostic applications and therapeutic applications.
- the gonadic system is the most fragile of the endocrine systems. In various polyendocrinopathies, impairment of gonadic function may be the first sign of the illness. In the face of irregularities in the menstrual cycle, an investigation of the anti-ovary antibodies can be the first sign of an incipient autoimmune ovaritis.
- FIG. 1 shows the increase in the levels of anti-peptide SEQ ID NO: 1 antibodies
- FIG. 2 shows the increase in the levels of anti-peptide SEQ ID NO: 1 antibodies, after the first IVF attempt and the increase in the IgM SEQ ID NO: 1 after the subsequent IVF attempts,
- FIG. 3 shows a comparison of the change in the anti-ovary antibodies and anti-peptide SEQ ID NO: 1, before and after puncture in a population of women suffering from tubal sterility
- FIG. 4 demonstrates the higher levels of anti-peptide SEQ ID NO: 1 antibodies, in the absence of biological pregnancy measured from the increase in the levels of HCG (solid columns).
- the concentration of molecules to be adsorbed was determined by checkerboard experiments for each antigen. It is about 1 ⁇ g per well.
- the binding of the antigens to the solid phase is performed in one night at +4° C. in the amount of 100 ⁇ l per well of the solution of antigen in carbonate-bicarbonate buffer.
- the plate is emptied.
- the sites of the solid phase still unoccupied are saturated on incubation for one hour at 37° C. with 200 ⁇ l per well of 5% powdered milk reconstituted in PBS.
- the samples to be tested are diluted in PBS to which 0.5% BSA and 0.2% Tween 20 have been added: dilution to 1/50 for the search for anti-ovary and anti-corpus luteum antibodies.
- the plate is emptied and washed 3 times in PBS.
- the samples are distributed in the amount of 100 ⁇ l per well.
- the plate is incubated for 45 minutes at 37° C.
- the anti-isotypes are diluted in the same solution that was used for the dilution of the samples:
- the plate is again emptied and washed 3 times in PBS. Then the anti-isotypes are distributed in the amount of 100 ⁇ l per well. The plate is incubated for 45 minutes at 37° C.
- the developer solution is prepared on the spot, as follows for one plate:
- optical density O.D.
- ratios relative to a control sample at the limit of positivity Any ratio greater than 1 is considered as positive.
- FSH the peptides consisting of the sequence of amino acids 78-93 and 80-87 of the ⁇ -chain of FSH, identified respectively by SEQ ID No.1 and 5, are simultaneously recognized by serums containing anti-ovary antibodies and by 2 anti- ⁇ FSH monoclonal antibodies (property of bioMérieux, 22A3G7; 5H3E8), which have the characteristic of being immunoreactive with metrodine and ovarian extracts, while an anti- ⁇ -FSH monoclonal antibody (property of bioMérieux, 7G5A1) only recognizing metrodine does not react with this sequence.
- the immunoenzymatic technique used is that described in Example 1.
- the patients included in the study were all scheduled for IVF. Their average age was 32.7 ⁇ 4.2 years. The average duration of the sterility was 4.8 ⁇ 2.8 years.
- the aetiology of the sterility which had led the couple to IVF was of tubal origin in 24.9% of the cases, of masculine origin in 18.2% of the cases, of idiopathic origin in 8.6%, due to an ovarian dystrophy (PCO) in 3.8% of the cases, and due to an endometriosis in 2.8% of the cases.
- PCO ovarian dystrophy
- endometriosis in 2.8% of the cases.
- at least two of the above aetiologies were present together, constituting mixed aetiologies.
- the serum was collected on the eighth day of the stimulation, and in 84 cases the serum was collected 15 days after the puncture.
- follicular puncture stimulates the appearance of anti-peptide SEQ ID NO:1 antibodies, and patients displaying such antibodies in their serum have less chance of securing a pregnancy after IVF.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
An oligopeptides comprising the following sequence Thr Gln Cys His Cys Gly Lys Cys (SEQ ID NO: 5) may be used as an antigenic compound capable of being recognized by anti-ovary antibodies and as an immunogenic compound capable of inducing the production of anti-ovary antibodies. In addition, the oligopeptides may be used to detect and/or quantify anti-ovary antibodies.
Description
- The present invention concerns immunology and its direct impact in endocrinology, both in man and in animals. More particularly, this impact concerns the reproductive system. It is in fact through pathologies such as repeated spontaneous abortions, antiphospholipid antibody syndrome and preeclampsia that dysimmune mechanisms have been observed in gynaecology and obstetrics.
- The development of in vitro fertilization (IVF) techniques has greatly contributed to improving understanding of the mechanisms of human fertilization. However, this technique sometimes encounters unexpected failures. Involvement of unfavorable immune reactions generated by the technique itself has been envisaged, on account of the considerable traumas inflicted on the ovary in the course of the hormonal stimulation and follicular punctures, which can liberate substantial quantities of potentially antigenic material into the peritoneal cavity.
- Previous studies have revealed antigenic components in the thecae, constituents of the ovary, and the presence of serum antibodies directed against the cells of the ovarian thecae or against the corpus luteum has been reported in different pathological contexts (adrenal insufficiency, ovarian insufficiency, to a greater or lesser extent associated with polyendocrinopathy) (6). Furthermore, SHIVERS et al. (1) have shown that antibodies produced against ovarian antibodies, called anti-ovary antibodies (AOA) inhibited in vitro fertilization in the hamster.
- The publication by SAXENA and RATHNAM (“Chemical synthetesis [sic] of peptide fragments of the hormone-specific beta-subunit of human follicule-[sic]-stimulating hormone”, Biochemistry, Vol. 24, No.3, 1985, pp 813-816) discloses the chemical synthesis of peptides in order to determine the specific antigenic determinants of the human FSH hormone. These are the peptides V3+½ (corresponding to the amino acids 76-118 of the β-subunit of FSH) and V1+C1 (corresponding to the amino acids 1-33 of the β-subunit of FSH) which are presented as being the antigenic determinants of the hormone FSH which are reactive toward antibodies to the hormones LH and TSH, which proves a homology of the antigenic sites for the three hormones FSH, LH and TSH.
- The publication by SANTA-COLOMA et al. (“Serine analogues of hFSH-beta-(33-53) and hFSH-beta-(81-95) inhibit hFSH binding to receptor”, Biochemical and Biophysical Research Communications, Vol. 184, No.3, 15 May 1992, pp 1273-1279) discloses synthetic peptides corresponding to the amino acids 33-53 and 81-95 of the β-subunit of FSH, containing free sulfydryl groups, which make it possible to inhibit the binding of the hormone FSH to its receptor and which also display a partial agonist activity on the said FSH receptor. It is stated that the 4 cysteine residues are not essential to the binding to the receptor but are important for the partial agonist activity of these peptides on the receptor.
- The publication by TANG et al. (“Premature ovarian failure: a search for circulating factors against gonadotrophin receptors, American Journal of Obstretics [sic] and Gynecology, Vol. 146, No.7, 1 Aug. 1983, pp 813-821) presents a study performed on nine patients displaying early menopause. This study suggests that factors active against the gonadotrophin receptor seem not to be involved in the majority of patients displaying premature failure of the ovaries. Instead, a factor active against the FSH receptor, which may be an antibody, is suggested as being possibly present in patients displaying early menopause and auto-immunity.
- The inventors of the present invention have surprisingly discovered that a well defined peptide sequence, which corresponds in its primary structure to a part of the β-subunit of FSH, displayed an antigenic and immunogenic character toward anti-ovary antibodies such as previously defined.
- In the course of previous studies, the authors of the present invention demonstrated the existence of a correlation between the level of anti-ovary antibodies observed and the failures of IVF attempts (2).
- The authors then became interested in the antigens potentially involved in the generation of these auto-immune responses, and firstly isolated and characterized an immunodominant peptide reacting with the anti-ovary antibodies, then demonstrated the value of this peptide in the detection of AOAs.
- The importance of this detection has been demonstrated, in different pathologies resulting in sterility, by the authors of the present invention.
- In examining the AOA levels before and after follicular puncture, they observed, in women undergoing a first IVF attempt, a level of AOA higher than the level in control women, even when for these women an IVF protocol had been recommended for different types of sterility, namely sterility of tubal origin, of idiopathic origin, resulting from endometriosis or linked with severe ovulation disorders.
- The detection of anti-ovary antibodies in a sterility pathology, after one or several vain IVF attempts, can become decisive to the policy to be followed concerning these failures. The authors have in fact demonstrated the efficacy of corticotherapy on the favorable outcome of an IVF attempt (3).
- The study of ovarian auto-immunity is nowadays essentially addressed using animal tissue substrates or animal ovarian extracts (4). The ovarian extract used by MONCAYO et al. was of animal, namely bovine, origin. It has not been demonstrated that the antigens recognized were actually the same in the human species and in cattle.
- According to the present invention, an antigenic peptide capable of replacing ovarian extracts, and follicle stimulating hormone (FSH or gonadotrophin A) which remains a product difficult to purify, and only on the market in recombinant forms, is provided.
- The immunochemical studies performed by the authors have thus made it possible to detect an oligopeptide immunodominant toward the AOAs, belonging to the β-chain of FSH.
- Thus, the first object of the invention is an oligopeptide consisting of the reference peptide sequence Thr Gln Cys His Cys Gly Lys Cys (SEQ ID NO: 5), or any peptide sequence, functional variant of the said reference sequence, in the sense that the first displays an antigenicity, and/or an immunogenicity toward anti-ovary antibodies equivalent to the antigenicity and/or the immunogenicity of the second.
- A functional variant of the said reference sequence is advantageously obtained by modifying the hydrocarbon residue of at least one of the amino acids of the said reference sequence, while conserving an antigenicity identical or similar to that of the said reference sequence, or else by modifying the hydrocarbon residue of at least one of the amino acids of the said reference sequence, while substantially retaining the hydrophilic/hydrophobic character of the said hydrocarbon residue.
- By equivalent activity is understood an identical or similar antigenic and/or immunogenic activity, even if differences of degree may exist in the antigenic and/or immunogenic responses.
- An oligopeptide of the invention can thus consist of a peptide sequence corresponding to the formula:
Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8,
in which formula: - Xaa1 represents threonine,
- Xaa2 represents glutamine,
- Xaa3 represents cysteine,
- Xaa4 represents histidine,
- Xaa5 represents cysteine,
- Xaa6 represents glycine,
- Xaa7 represents lysine, and
- Xaa8 represents cysteine,
- the said sequence being identified by SEQ ID NO: 5,
or a peptide sequence which is a functional variant of SEQ ID NO: 5. - Preferably, the said functional variant sequence corresponds to the formula
Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8,
in which formula: - Xaa1 represents threonine or the unit NH2—CH(R1)COOH where R1 is an oxygenated hydrocarbon radical conferring on the said variant sequence an antigenicity identical or similar to that of SEQ ID NO: 5,
- Xaa2 represents glutamine or the unit NH2—CH(R2)COOH where R2 is an oxygenated and/or aminated hydrocarbon radical conferring on the said variant sequence an antigenicity identical or similar to that of SEQ ID NO: 5,
- Xaa3 represents cysteine or the unit NH2—CH(R3)COOH where R3 is a sulfurated hydrocarbon radical conferring on the said variant sequence an antigenicity identical or similar to that of SEQ ID NO: 5,
- Xaa4 represents histidine or the unit NH2—CH(R4)COOH where R4 is an aminated hydrocarbon radical conferring on the said variant sequence an antigenicity identical or similar to that of SEQ ID NO: 5,
- Xaa5 represents cysteine or the unit NH2—CH(R5)COOH where R5 is a sulfurated hydrocarbon radical conferring on the said variant sequence an antigenicity identical or similar to that of SEQ ID NO: 5,
- Xaa6 represents glycine or the unit NH2—CH(R6)COOH where R6 is a hydrocarbon radical conferring on the said variant sequence an antigenicity identical or similar to that of SEQ ID NO: 5,
- Xaa7 represents lysine or the unit NH2—CH(R7)COOH where R7 is an aminated hydrocarbon radical conferring on the said variant sequence an antigenicity identical or similar to that of SEQ ID NO: 5,
- Xaa8 represents cysteine or the unit NH2—CH(R8)COOH where R8 is a sulfurated hydrocarbon radical conferring on the said variant sequence an antigenicity identical or similar to that of SEQ ID NO: 5.
- Advantageously, the constituent radicals R1 and/or R2 and/or R3 and/or R4 and/or R5 and/or R6 and/or R7 and/or R8 of the said units are respectively selected among radicals conferring on the said units a hydrophilicity/hydrophobicity identical or similar to that of the respectively corresponding amino acids.
- It is evident from the general knowledge of the person skilled in immunology and peptide synthesis that the hydrophilic/hydrophobic character of the constituent units of proteins/peptides is of importance to the antigenic power of the latter. Moreover, many works on general biochemistry (5) have classified the 20 amino acids on the basis of their greater or lesser hydrophobic/hydrophilic character. According to the present invention, it is considered that the selection of the radicals R1 to R8 in the above formula can be made by the aforesaid skilled person with the aid of the said works, and that he in addition has routine experimental protocols available for determining the hydrophilic/hydrophobic character of the constituent unit that he has selected.
- Of course, other physicochemical parameters of the amino acids can be used to determine variant sequences, such as for example the pKa constant.
- As functional variants of the peptide sequence SEQ ID No.5, the oligopeptide consisting of the peptide sequence SEQ ID No.1 for example, may be cited. Example 2 below in fact demonstrates identical activity for the oligopeptides SEQ ID No.1 and 5. The oligopeptides SEQ ID No.2, 3 and 4, having weaker activity than the oligopeptides cited above, are considered in the present invention as functional variants. In fact, inasmuch as their antigenic or immunogenic activity toward anti-ovary antibodies is weaker, but useful all the same, for example mixed with other oligopeptides of the same activity, in a diagnostic kit, these oligopeptides are functional variants of SEQ ID No.5.
- The oligopeptides described at the end of the specification are:
-
- SEQ ID No.1: linear sequence of 16 amino acids corresponding to the sequence of amino acids 78-93 of the β-chain of FSH,
- SEQ ID No.2: sequence of 16 amino acids, bridged by a disulfide bond in position 5 and 7, corresponding to the sequence of amino acids 78-93 of the β-chain of FSH,
- SEQ ID No.3: sequence of 16 amino acids, bridged by a disulfide bond in position 5 and 10, corresponding to the sequence of amino acids 78-93 of the β-chain of FSH,
- SEQ ID No.4: sequence of 16 amino acids, bridged by a disulfide bond in position 7 and 10, corresponding to the sequence of amino acids 78-93 of the β-chain of FSH,
- SEQ ID No.5: linear sequence of 8 amino acids corresponding to the sequence of amino acids 80-87 of the β-chain of FSH.
- The surprising feature of the invention is that the oligopeptides of the invention, such as those represented by SEQ ID No.1 and 5, the primary amino acid structure of which corresponds respectively to the amino acids 78-93 and 80-87 of the P-chain of FSH, although probably having a three-dimensional structure different from that of the β-chain of FSH, display an antigenic and/or immunogenic activity toward anti-ovary antibodies.
- In a preferred mode of implementation according to the invention, the oligopeptide has the peptide sequence identified by SEQ ID No.5.
- In another preferred mode of implementation according to the invention, the oligopeptide has the peptide sequence identified by SEQ ID No.1.
- In yet another mode of implementation according to the invention, the oligopeptide has the peptide sequence identified by SEQ ID No.2 or 3 or 4, as identified at the end of the specification.
- A second object of the present invention is an antigenic compound capable of being recognized by the anti-ovary antibodies, or an immunogenic compound capable of inducing the production of anti-ovary antibodies, the said compound corresponding to any one at least of the following definitions:
-
- a compound having a peptide sequence including the sequence of the oligopeptide described above, and preferably including the sequence SEQ ID No.5; in particular, such a compound has a peptide sequence which includes or which consists of SEQ ID No.1, as identified at the end of the specification;
- a compound consisting of FSH or a functional variant of FSH;
- a compound consisting of the P-chain of FSH;
- a compound whose antigenicity or immunogenicity is representative of the anti-genicity or immunogenicity of the crude ovarian antigens, the primary structure of the said compound including a peptide sequence corresponding to the sequence of amino acids 78-93 of the β-chain of the FSH of the human race or of any animal species, the said sequence being immunodominant and being recognized by the anti-ovary antibodies of the said human race or of the said species.
- Another object of the invention is a composition antigenic or immunogenic toward anti-ovary antibodies, including an antigenic or immunogenic compound such as defined above.
- One application of an oligopeptide or of a compound of the invention lies in the detection and/or quantification of anti-ovary antibodies. Thus a third object of the invention is a process for detection and/or quantification of anti-ovary antibodies in a biological sample, including the stage consisting in placing the said biological sample in contact with at least one peptide or one compound of the invention, and in observing the formation of an antigen-antibody complex between the said peptide or compound and an anti-ovary antibody.
- The formation of the aforesaid complex can be detected by different classical bioassay formats, known to the skilled person, such as immunocytochemical and immunoenzymatic (ELISA) techniques, competition techniques and “sandwich” techniques.
- In accordance with this process, the biological sample is advantageously selected among the blood serum, the follicular liquid, the peritoneal liquid, the cervical mucus and the saliva.
- The stage of observation of the formation of an antigen-antibody complex is preferably effected by the immunoenzymatic technique called ELISA, with which it has been possible to obtain results perfectly correlated those [sic] obtained by the reference technique for the skilled person, namely indirect immunofluorescence.
- Finally, the last objects of the invention are firstly a reagent for detection and/or quantification of anti-ovary antibodies including at least one peptide or one compound of the invention, and secondly a kit for detection and/or quantification of anti-ovary antibodies including at least the said reagent.
- Before presenting the benefits of the invention and describing it in more detail, certain terms used in the present text are defined below.
- A peptide sequence, functional variant of the reference peptide sequence (SEQ ID NO: 5) is a sequence of amino acids, called modified, differing from the sequence (SEQ ID NO: 5) by modifications which confer on the said functional variant sequence an antigenicity identical or similar to that of the reference sequence. The modifications of the said sequence can concern its size, and each of the amino acids that constitute it. Such modifications are in particular selected among substitutions, deletions and additions of amino acids in the sequence of the first oligopeptide, but also among replacement of an amino acid of the L series by an amino acid of the D series, modification of the side-chains of the amino acids, modification of the peptide bonds such as carba, retro, inverso, retro-inverso, reduced or methylene-oxy bonds, subject to the condition that these modifications do not result in any significant alteration of the antigenic properties of the said sequence toward anti-ovary antibodies.
- As an example of substitution, and as previously mentioned, an amino acid of SEQ ID No: 5 can be replaced by another amino acid of the same hydrophilicity/hydrophobicity or of comparable hydrophilicity/hydrophobicity.
- The competent skilled person, who routinely utilizes the techniques at his disposal, in particular the techniques of automated peptide synthesis and the techniques of determination of the antigenicity of a peptide such as ELISA tests, is capable, in a first stage, of synthesizing a modified sequence such as defined above, and, in a second stage, of testing the antigenicity of the peptide obtained. If the latter displays an antigenicity at least substantially equivalent to that of the said reference sequence, it corresponds to the definition of functional variant sequence of the said reference sequence. The skilled person can in particular refer to the examples 2 and 3 below, which describe a protocol to be followed for comparing the antigenicity of two peptides toward AOAs.
- A compound of the invention includes a sequence of a variable number of amino acids, including at least the sequence of one oligopeptide of the invention. It can in particular consist of a protein, a glycoprotein, a fusion protein or a fusion peptide. It can moreover be bound on a solid support.
- An oligopeptide or a polypeptide of the invention may be obtained by any obtention route and in particular chemical synthesis or genetic recombination.
- The objects of the invention are also of value outside the study of physiopathogenic hypotheses relating to certain clinical situations, such as mentioned previously. In fact, the provision of a reliable test for estimation of anti-ovary antibodies can have other diagnostic applications and therapeutic applications.
- The gonadic system is the most fragile of the endocrine systems. In various polyendocrinopathies, impairment of gonadic function may be the first sign of the illness. In the face of irregularities in the menstrual cycle, an investigation of the anti-ovary antibodies can be the first sign of an incipient autoimmune ovaritis.
- Two other groups of pathology are directly concerned by this type of investigation. These are the group of early menopauses and the group of ovarian dystrophies.
- These groups are very heterogeneous in their mechanisms and the detection and/or quantification of anti-SEQ ID NO:1 antibodies makes it possible to identify more homogeneous subgroups with possible therapeutic implications.
- In the sterility field, patients suffering from so-called “idiopathic” sterility can benefit from this type of analysis, in the same way as the search for other autoantibodies.
- Endometriosis, a disease whose mechanisms are still unknown today, obviously occurs in patients in this particular field. Many autoantibodies have been identified in patients suffering from this disease. The mechanism of the sterility is not always clear in these patients. The search for anti-peptide SEQ ID NO: 1 antibodies is of great interest here both on the physiopathological level and on the therapeutic level.
- Indeed, the search for such autoantibodies can also have direct therapeutic implications.
- The characteristics and advantages of the objects of the present invention will be evident from the following Examples 1 to 4, supported by FIGS. 1 to 4, among which:
-
FIG. 1 shows the increase in the levels of anti-peptide SEQ ID NO: 1 antibodies, -
FIG. 2 shows the increase in the levels of anti-peptide SEQ ID NO: 1 antibodies, after the first IVF attempt and the increase in the IgM SEQ ID NO: 1 after the subsequent IVF attempts, -
FIG. 3 shows a comparison of the change in the anti-ovary antibodies and anti-peptide SEQ ID NO: 1, before and after puncture in a population of women suffering from tubal sterility, and -
FIG. 4 demonstrates the higher levels of anti-peptide SEQ ID NO: 1 antibodies, in the absence of biological pregnancy measured from the increase in the levels of HCG (solid columns). - a) Reagents
-
- Antigen:
- Ovary
- Corpus luteum
- FSH (Metrodine®, Serono, Levallois-Perret, France) Peptides SEQ ID Nos: 1 to 5
- Carbonate-bicarbonate buffer 0.1 M, pH 9.6
- Phosphate buffer saline (PBS) 0.001 M, pH 7.4 (PBS)
- Tween 20 (Sigma, St Louis, Mo., USA)
- Gloria powdered skimmed milk
- Bovine serum albumin (BSA) (Sigma)
- Peroxidase-conjugated anti-human immunoglobulins (IgG, IgA, IgM) (Miles, Napperville, Mass., USA)
- Phosphate-citric acid buffer 0.1 M, pH 5.5
- 30 volume hydrogen peroxide (Gifrer Barbezat, Décines, France)
- Ortho-phenylenediamine (OPD) (Sigma)
- 2 N sulfuric acid (Prolabo, Paris, France)
- Antigen:
- b) Apparatus
-
- Maxisorp plates (Nunc, Roskilde, Denmark)
- Precision balance (Sartorius, Osi, Paris, France)
- Multiskan II spectrophotometer, equipped with a 492 nm filter (Flow laboratories, Helsinki, Finland)
- Titersoft software (Flow Laboratories)
- c) Method
- The concentration of molecules to be adsorbed was determined by checkerboard experiments for each antigen. It is about 1 μg per well.
- The binding of the antigens to the solid phase is performed in one night at +4° C. in the amount of 100 μl per well of the solution of antigen in carbonate-bicarbonate buffer. The plate is emptied. The sites of the solid phase still unoccupied are saturated on incubation for one hour at 37° C. with 200 μl per well of 5% powdered milk reconstituted in PBS.
- The samples to be tested are diluted in PBS to which 0.5% BSA and 0.2% Tween 20 have been added: dilution to 1/50 for the search for anti-ovary and anti-corpus luteum antibodies. The plate is emptied and washed 3 times in PBS. The samples are distributed in the amount of 100 μl per well. The plate is incubated for 45 minutes at 37° C.
- The anti-isotypes are diluted in the same solution that was used for the dilution of the samples:
-
- 1/10,000 for the anti-IgGs
- 1/5000 for the anti-IgAs
- 1/5000 for the anti-IgMs.
- The plate is again emptied and washed 3 times in PBS. Then the anti-isotypes are distributed in the amount of 100 μl per well. The plate is incubated for 45 minutes at 37° C.
- The developer solution is prepared on the spot, as follows for one plate:
-
- 12 ml of phosphate-citric acid buffer
- 6 mg of OPD
- 12 ml of H2O2.
- After 3 further washings of the plate, 100 μl of developer solution are distributed into each well. After appearance of a yellow colour of greater or lesser intensity, the reaction is stopped with 50 μl of H2SO4. The plate is read on the spectrophotometer at 492 nm using the Multiskan II reader.
- The results are firstly expressed as optical density (O.D.) then calculated as ratios relative to a control sample at the limit of positivity. Any ratio greater than 1 is considered as positive.
- The inventors firstly discovered that FSH, then the peptides consisting of the sequence of amino acids 78-93 and 80-87 of the β-chain of FSH, identified respectively by SEQ ID No.1 and 5, are simultaneously recognized by serums containing anti-ovary antibodies and by 2 anti-βFSH monoclonal antibodies (property of bioMérieux, 22A3G7; 5H3E8), which have the characteristic of being immunoreactive with metrodine and ovarian extracts, while an anti-β-FSH monoclonal antibody (property of bioMérieux, 7G5A1) only recognizing metrodine does not react with this sequence.
- Given that the sequence of amino acids 78-93 of the β-chain of FSH contains 3 cysteines, 4 peptides of 16 amino acids corresponding to the different disulfide bridge possibilities were synthesized.
- These four peptides are identified by the respective references SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, and are described at the end of the specification.
- These four peptides obtained in lyophilized form were, after reconstitution and dialysis, used as antigens in a series of ELISA tests on 30 sera from patients.
- Moreover, these same sera were tested against the crude ovarian antigens.
- The immunoenzymatic technique used is that described in Example 1.
- The results of the correlation obtained between the reactivity of the sera toward the ovarian antigen and that of the same sera toward each of the peptides tested, and expressed by an r value, are shown in Table I below:
TABLE I SEQ ID No. SEQ ID No. SEQ ID No. SEQ ID No. 1 2 3 4 IgG AOA 0.74 0.44 0.79 0.59 IgA AOA 0.46 0.28 0.49 0.49 IgM AOA 0.81 0.75 0.71 0.69 - It is found that the best correlation coefficients are obtained for the IgMs on the one hand (which had already been noted with the commercial FSH) and for the peptide SEQ ID NO: 1 on the other hand.
- The same results as those obtained for the peptide SEQ ID No.1 were obtained with the peptide SEQ ID No.5, FSH and the β-chain of FSH.
- Two centre [sic] and ninety-five sera were tested in duplicate, using the immunoenzymatic method described above, with, firstly, the total ovarian extract, and, secondly, the peptide SEQ ID NO: 1. For each antigen, the three immunoglobulin isotypes IgG, IgA and IgM were studied.
- a) Population Studied
- The patients included in the study were all scheduled for IVF. Their average age was 32.7±4.2 years. The average duration of the sterility was 4.8±2.8 years.
- The aetiology of the sterility which had led the couple to IVF was of tubal origin in 24.9% of the cases, of masculine origin in 18.2% of the cases, of idiopathic origin in 8.6%, due to an ovarian dystrophy (PCO) in 3.8% of the cases, and due to an endometriosis in 2.8% of the cases. In 41.7%, at least two of the above aetiologies were present together, constituting mixed aetiologies.
- In 209 cases the serum was collected on the eighth day of the stimulation, and in 84 cases the serum was collected 15 days after the puncture.
- b) Results
- The results of [sic] the correlation obtained between the reactivity of the sera toward the crude ovarian antigen and that of the same sera toward the peptide SEQ ID NO:1 tested, and expressed by an r value, are shown in Table II below:
TABLE II IgG SEQ ID IgA SEQ ID IgM SEQ ID No. 1 No. 1 No. 1 IgG AOA 0.18 0.12 NS IgA AOA 0.12 0.11 0.01 IgM AOA 0.10 0.06 0.27 - A correlation is observed between IgG AOA and IgG SEQ ID NO:1 (r=0.18, p=0.002), and between IgM AOA and IgM SEQ ID NO:1 (r=0.27, p<0.00001). On the other hand, no correlation is observed between IgA AOA and IgA SEQ ID NO:1 (r=0.10, p=0.06).
- Whatever the combination of number of IVF attempts made and sterility aetiology, an increase in anti-peptide SEQ ID NO:1 antibodies was observed after puncture, with a statistically significant difference for the IgM SEQ ID NO:1 (p=0.005) (see
FIG. 1 ). - On the basis of the number of IVF attempts made, before and after puncture, and as shown in
FIG. 2 , the following are observed: - in first IVF attempt patients, an increase in anti-peptide SEQ ID NO:1 antibodies, after the follicular puncture, whatever the isotype considered,
- in multiply-punctured patients, a decrease in the IgG and IgA SEQ ID NO:1 post-puncture and a very clear and statistically significant increase in the IgM SEQ ID NO:1 (p=0.01).
- on the basis of the aetiology of the sterility and before and after puncture
- For the aetiology of tubal origin, included as it serves as a reference for IVF (IgA p=0.04 and IgM p=0.027), an indisputable increase is observed in the AOAs of isotypes A and M, after puncture, but an increase in the anti-peptide SEQ ID NO:1, which is clearer and statistically significant for these same isotypes (see
FIG. 3 ). - On the basis of the number of ovocytes and embryos obtained
- The presence of anti-peptide SEQ ID NO:1 antibodies appears deleterious to the obtention of ovocytes and embryos.
- An attempt was made to define a limit threshold depending on the isotype concerned pre-puncture. From 151 measurements (a certain number of attempts did not get as far as the follicular puncture), it was possible to determine this threshold for the IgA SEQ ID NO:1 at 0.75, for the ovocytes (9.4 vs. 11.8 ovocytes), and at 0.60, for the embryos (3.1 vs. 4.9 embryos).
- It should be noted that this threshold is lower than that defined for the IgA AOAs (1.7 for the ovocytes and the embryos).
- On the basis of the outcome of the attempt
- The mean levels of anti-peptide SEQ ID NO:1 antibodies were compared in relation to whether the plasma HCG (chorionic gonadotrophin) estimation was positive (biological pregnancy) or negative (absence of implantation).
- In accordance with
FIG. 4 , on average lower antibody levels were found when the HCG was positive. - These results demonstrate that the peptide SEQ ID NO:1 makes it possible sensitively and specifically to detect antibodies displaying variations parallel to those of antibodies directed against the total ovarian extract.
- Moreover, follicular puncture stimulates the appearance of anti-peptide SEQ ID NO:1 antibodies, and patients displaying such antibodies in their serum have less chance of securing a pregnancy after IVF.
-
- (1) C. A. SHIVERS and B. S. DUNBAR, (1977) Autoantibodies to zona pellucida: a possible cause of infertility in women. Science, 197: 1087-1190
- (2) P. BARBARINO-MONNIER et al., Fertility and Sterility, Vol. 56, No.5 (1991) 928-932
- (3) P. BARBARINO-MONNIER et al., Human Reproduction, Vol. 10, No.8 (1995), 2006-2007
- (4) H. E. MONCAYO-NAVEDA, R. MONCAYO, R. BENZ, A. WOLF and Ch. LAURITZEN (1989) Organ specific antibodies against ovary in patients with systemic lupus erythematosus. Am. J. Obstet. Gynecol., 160: 1227-1229
- (5) A. L. LEHNINGER, Translation of the second edition of: Biochemistry, the molecular basis of cell structure and function, Chapter 4: The Proteins: The constituent amino acids, p. 69 to 74 (1979)
- (6) R. MONCAYO and H. E. MONCAYO, Journal of Internal Medicine (1993), 234: 371-378.
Claims (18)
1-3. (canceled)
4. A process for detection of anti-ovary antibodies in a biological sample, comprising:
placing said biological sample in contact with at least one oligopeptide comprising a reference peptide sequence SEQ ID NO: 5, or any peptide sequence that is a functional variant of said reference sequence in that it displays an antigenicity and/or an immunogenicity toward anti-ovary antibodies identical or similar to the antigenicity and/or the immunogenicity of the reference peptide, and
observing the formation of an antigen-antibody complex between said oligopeptide and an anti-ovary antibody.
5. The process according to claim 4 , wherein the functional variant differs from said reference sequence by modification of the hydrocarbon residue of at least one amino acid of said reference sequence.
6. The process according to claim 5 , wherein the modification substantially conserves the hydrophilic or hydrophobic character of the hydrocarbon residue of the at least one amino acid.
7. The process according to claim 4 , wherein the oligopeptide comprises a sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5.
8. The process according to claim 7 , wherein the oligopeptide consists of a sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5.
9. The process according to claim 4 , wherein the biological sample is selected from the group consisting of blood serum, follicular liquid, peritoneal liquid, cervical mucus and saliva.
10. The process according to claim 4 , wherein the formation of an antigen-antibody complex is observed by an immunoenzymatic technique.
11. The process according to claim 4 , wherein said oligopeptide consists of FSH, a functional variant of FSH or the β-chain of FSH.
12. The process according to claim 4 , wherein said oligopeptide comprises a peptide sequence corresponding to the sequence of amino acids 78-93 of the β-chain of FSH.
13-20. (canceled)
21. The process according to claim 4 , further comprising quantifying the amount of anti-ovary antibodies in the biological sample.
22. The process according to claim 4 , wherein the oligopeptide comprises SEQ ID NO: 5.
23. The process according to claim 22 , wherein the oligopeptide comprises a peptide sequence selected from the group consisting of SEQ ID NOs: 1-4.
24. The process according to claim 22 , comprising a disulfide bond between two cysteines of SEQ ID NO: 5.
25. The process according to claim 4 , wherein said oligopeptide comprises a peptide sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8, wherein:
Xaa1 is NH2—CH(R1)COOH, where R1 is an oxygenated hydrocarbon radical;
Xaa2 is NH2—CH(R2)COOH, where R2 is an oxygenated and/or aminated hydrocarbon radical;
Xaa3 is NH2—CH(R3)COOH, where R3 is a sulfurated hydrocarbon radical;
Xaa4 is NH2—CH(R4)COOH, where R4 is an aminated hydrocarbon radical;
Xaa5 is NH2—CH(R5)COOH, where R5 is a sulfurated hydrocarbon radical;
Xaa6 is NH2—CH(R6)COOH, where R6 is a hydrocarbon radical;
Xaa7 is NH2—CH(R7)COOH, where R7 is an aminated hydrocarbon radical; and
Xaa8 is NH2—CH(R8)COOH, where R8 is a sulfurated hydrocarbon radical.
26. The process according to claim 25 , wherein:
Xaa1 is threonine or an amino acid having substantially the same hydrophilic or hydrophobic character of threonine;
Xaa2 is glutamine or an amino acid having substantially the same hydrophilic or hydrophobic character as glutamine;
Xaa3 is cysteine or an amino acid having substantially the same hydrophilic or hydrophobic character as cysteine;
Xaa4 is histidine or an amino acid having substantially the same hydrophilic or hydrophobic character as histidine;
Xaa5 is cysteine or an amino acid having substantially the same hydrophilic or hydrophobic character as cysteine;
Xaa6 is glycine or an amino acid having substantially the same hydrophilic or hydrophobic character as glycine;
Xaa7 is lysine or an amino acid having substantially the same hydrophilic or hydrophobic character as lysine; and
Xaa8 is cysteine or an amino acid having substantially the same hydrophilic or hydrophobic character as cysteine.
27. The process according to claim 4 , wherein said oligopeptide contains no more than 16 amino acids.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/142,327 US20050260200A1 (en) | 1996-12-31 | 2005-06-02 | Antigenic peptides reacting with anti-ovary antibodies |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9616385 | 1996-12-31 | ||
FR9616385A FR2757862B1 (en) | 1996-12-31 | 1996-12-31 | ANTIGENIC PEPTIDES REACTING WITH ANTI-OVARY ANTIBODIES |
PCT/IB1997/001611 WO1998029450A1 (en) | 1996-12-31 | 1997-12-31 | Antigenic peptides reacting with anti-ovary antibodies |
US09/331,872 US6602853B1 (en) | 1996-12-31 | 1997-12-31 | Antigenic peptides reacting with anti-ovary antibodies |
US10/461,493 US20030199452A1 (en) | 1996-12-31 | 2003-06-16 | Antigenic peptides reacting with anti-ovary antibodies |
US11/142,327 US20050260200A1 (en) | 1996-12-31 | 2005-06-02 | Antigenic peptides reacting with anti-ovary antibodies |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/461,493 Continuation US20030199452A1 (en) | 1996-12-31 | 2003-06-16 | Antigenic peptides reacting with anti-ovary antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050260200A1 true US20050260200A1 (en) | 2005-11-24 |
Family
ID=9499441
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/331,872 Expired - Fee Related US6602853B1 (en) | 1996-12-31 | 1997-12-31 | Antigenic peptides reacting with anti-ovary antibodies |
US10/461,493 Abandoned US20030199452A1 (en) | 1996-12-31 | 2003-06-16 | Antigenic peptides reacting with anti-ovary antibodies |
US11/142,327 Abandoned US20050260200A1 (en) | 1996-12-31 | 2005-06-02 | Antigenic peptides reacting with anti-ovary antibodies |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/331,872 Expired - Fee Related US6602853B1 (en) | 1996-12-31 | 1997-12-31 | Antigenic peptides reacting with anti-ovary antibodies |
US10/461,493 Abandoned US20030199452A1 (en) | 1996-12-31 | 2003-06-16 | Antigenic peptides reacting with anti-ovary antibodies |
Country Status (6)
Country | Link |
---|---|
US (3) | US6602853B1 (en) |
EP (1) | EP0968229A1 (en) |
AU (1) | AU5406098A (en) |
CA (1) | CA2276490A1 (en) |
FR (1) | FR2757862B1 (en) |
WO (1) | WO1998029450A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7321570B2 (en) * | 2004-02-03 | 2008-01-22 | Motorola, Inc. | Method and apparatus for dynamic power allocation to a multimedia broadcast/multicast service |
-
1996
- 1996-12-31 FR FR9616385A patent/FR2757862B1/en not_active Expired - Fee Related
-
1997
- 1997-12-31 EP EP97947825A patent/EP0968229A1/en not_active Withdrawn
- 1997-12-31 WO PCT/IB1997/001611 patent/WO1998029450A1/en not_active Application Discontinuation
- 1997-12-31 US US09/331,872 patent/US6602853B1/en not_active Expired - Fee Related
- 1997-12-31 CA CA002276490A patent/CA2276490A1/en not_active Abandoned
- 1997-12-31 AU AU54060/98A patent/AU5406098A/en not_active Abandoned
-
2003
- 2003-06-16 US US10/461,493 patent/US20030199452A1/en not_active Abandoned
-
2005
- 2005-06-02 US US11/142,327 patent/US20050260200A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
FR2757862B1 (en) | 1999-01-29 |
WO1998029450A1 (en) | 1998-07-09 |
EP0968229A1 (en) | 2000-01-05 |
FR2757862A1 (en) | 1998-07-03 |
AU5406098A (en) | 1998-07-31 |
CA2276490A1 (en) | 1998-07-09 |
US20030199452A1 (en) | 2003-10-23 |
US6602853B1 (en) | 2003-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Green et al. | The establishment of an ELISA for the detection of pregnancy-associated glycoproteins (PAGs) in the serum of pregnant cows and heifers | |
US7670852B2 (en) | Assays for preimplantation factor and preimplantation factor peptides | |
Canfield et al. | Development of an assay for a biomarker of pregnancy and early fetal loss. | |
Perkins et al. | Plasma measurements of corticotrophin-releasing hormone-binding protein in normal and abnormal human pregnancy | |
Anderson et al. | Increased ovulation rate in Merino ewes immunized against small synthetic peptide fragments of the inhibin α subunit | |
WO1987005702A1 (en) | Method of assay of inhibin | |
Hammer | Radioimmunoassay of 8-arginine-vasopressin (antidiuretic hormone) in human plasma | |
Lunenfeld et al. | Immunologic studies on gonadotropins. I. Immunogenic properties and immunologic characterization of human chorionic gonadotropin preparations (HCG) and their homologous antisera | |
Gallinelli et al. | Episodic secretion of activin A in pregnant women | |
AU684172B2 (en) | Method of genetic testing | |
US20050260200A1 (en) | Antigenic peptides reacting with anti-ovary antibodies | |
US5175148A (en) | Sperm antigen corresponding to a sperm autoantigenic epitope and methods of using the same | |
Davies | Antigenic analysis of immune complexes formed in normal human pregnancy. | |
Ferro et al. | Fertility‐Disrupting Potential of Synthetic Peptides Derived from the β‐Subunit of Follicle‐Stimulating Hormone | |
Mazlan et al. | Circulating levels of GH-releasing hormone and GH during human pregnancy | |
Brewer et al. | Gestational trophoblastic disease: selected clinical aspects and chorionic gonadotropin test methods | |
CN110317254A (en) | People MBP epitope peptide, antigen, antibody, application and chemical luminescence reagent kit | |
CN110317246A (en) | People MOG epitope peptide, antigen, antibody, application and chemical luminescence reagent kit | |
NAKAZAWA et al. | Immunohistochemical study on oxytocin-like substance in the human placenta | |
US7285524B1 (en) | Allo and auto-reactive T-cell epitopes | |
EP1518863A1 (en) | Antibodies modulating the activity of equine chorionic gonadotropin. | |
Sharpe-Timms et al. | Immunolocalization of progesterone-induced uterine protein-1 in human endometrium during the menstrual cycle and in the placenta throughout gestation | |
Furuhashi et al. | Specific Enzyme Immunoassay for Human Chorionic Gonadotropin using Antibody to the Synthtic Peptide Corresponding to the Carboxyl-Terminal Region of the β-subunit of hCG | |
CN116643056A (en) | Thyroid stimulating hormone receptor complex, kit, preparation method and application | |
Czuppon | Detection of anti-spermatozoal antibodies by a 125I-protein-A radioimmunobinding assay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |